BERWYN, PA — AscellaHealth has announced significant enhancements to its service model and infrastructure to support specialty and rare disease drug manufacturers facing heightened market disruption. As pressures mount from sudden formulary exclusions, biosimilar competition, and aggressive cost-containment strategies by payers, AscellaHealth is reinforcing its position as a strategic distribution and patient support partner.
“This is a wake-up call for biopharma manufacturers,” said Bill Oldham, chairman and president of AscellaHealth. “When preferred drug status can be lost overnight, it’s essential to have a pharmacy-first HUB partner that scales with you, minimizes disruption and delivers what’s best for patients and the product.”
The company cited UnitedHealthcare’s recent decision to remove Stelara® from its formulary as an example of the rapid changes impacting market access. In response, AscellaHealth is rolling out capabilities to ensure manufacturers maintain product visibility, continuity of care, and patient engagement even amid payer instability.
“AscellaHealth’s integrated HUB model ensures manufacturers maintain full control over their product, patients, and critical program data—regardless of payer shifts, employer transitions or market disruptions,” Oldham added. “Patients benefit from a consistent, reliable support system, while manufacturers can trust in a distribution partner that scales seamlessly and prioritizes uninterrupted access and continuity of care.”
Key service enhancements include:
- Formulary Strategy and Plan Design: AscellaHealth provides expertise to help manufacturers navigate shifting payer dynamics and preserve access to critical therapies.
- Mobile Patient Engagement: A new HIPAA-compliant mobile platform enables secure messaging, document exchange, and video support to boost adherence and satisfaction.
- Advanced Analytics and Monitoring: Powered by Microsoft’s business intelligence suite and proprietary tools, the platform delivers real-time insights, alerts, and reporting to inform better decision-making.
- Custom Distribution Models: Drawing on experience with exclusive, limited, and open channels, AscellaHealth supports manufacturers in selecting the most effective strategy and educating providers on site-of-care options.
The announcement also highlights infrastructure upgrades, including a phased rollout of WellSky’s software platform to enhance care coordination and workflows. The company is also expanding its Optime Care East facility, increasing its capacity to manage high-acuity patients and deliver global care management solutions.
AscellaHealth says these enhancements will help biopharma clients better respond to sudden disruptions while strengthening patient access and engagement in an increasingly complex and competitive pharmaceutical landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.